2. Protein Tyrosine Kinase/RTK
    Apoptosis
  3. Anaplastic lymphoma kinase (ALK)
    Apoptosis
  4. NVP-TAE 684

NVP-TAE 684  (Synonyms: TAE 684)

Cat. No.: HY-10192 Purity: 99.42%
COA Handling Instructions

NVP-TAE 684 (TAE 684) est un inhibiteur de ALK qui est très puissant et sélectif, qui bloque la croissance de lignées cellulaires dérivées d'ALCL et dépendantes d'ALK avec IC50 de valeurs comprises entre 2 et 10 nM.

NVP-TAE 684 (TAE 684) is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.

For research use only. We do not sell to patients.

NVP-TAE 684 Chemical Structure

NVP-TAE 684 Chemical Structure

CAS No. : 761439-42-3

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 143 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 143 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 106 In-stock
Estimated Time of Arrival: December 31
10 mg USD 158 In-stock
Estimated Time of Arrival: December 31
50 mg USD 422 In-stock
Estimated Time of Arrival: December 31
100 mg USD 594 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 14 publication(s) in Google Scholar

Top Publications Citing Use of Products

    NVP-TAE 684 purchased from MCE. Usage Cited in: Pigment Cell Melanoma Res. 2016 May;29(3):284-96.  [Abstract]

    Ltk inhibitor TAE684 partially rescues the ltkmne phenotype and decreases the number of iridophores. The number of iridophores is reduced in ltkmne/+ larvae treated with ALK inhibitor TAE684 from 82 to 105 hpf.

    NVP-TAE 684 purchased from MCE. Usage Cited in: ACS Chem Biol. 2012 Dec 21;7(12):1968-74.  [Abstract]

    TAE684 inhibits NPM-Ltk. Wild-type embryos are injected with 30 pg of psox10:NPM-Ltk and treated with 3 μM of TAE684. Incident light images at 3 dpf of control uninjected, nontreated embryo (a); NPM-Ltk injected, DMSO-treated sibling (b); and NPM-Ltk injected TAE684-treated siblings (c).

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    NVP-TAE 684 (TAE 684) is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM[1].

    IC50 & Target

    IC50: 2-10 nM (ALK-dependent cell lines)[1]
    In Vitro

    TAE684 inhibits the proliferation of Ba/F3 NPM-ALK cells with an IC50 of 3 nM, without affecting the survival of parental Ba/F3 cells at concentrations up to 1 μM. TAE684 inhibits STAT3 and STAT5 phosphorylation in a dose-dependent manner in both Ba/F3 NPM-ALK and Karpas-299 cells. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines[1].
    NVP-TAE684 markedly reduces cell survival in both sensitive H3122 and H3122 CR cells, but has little to no effect on the viability of other, non-ALK-dependent cancer cell lines. NVP-TAE684 treatment of H3122 CR cells suppresses phosphorylation of ALK, AKT, and ERK and induces marked apoptosis.
    TAE684 potently suppresses the survival of Ba/F3 cells expressing the EML4-ALK L1196M mutant[2].
    Neurite outgrowth induced by expression of the mALKR1279Q mutant is completely inhibited at 30 nM NVP-TAE684, which is comparable with the response seen with activated wt mALK[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    In Vivo

    NVP-TAE684 suppresses lymphomagenesis in two independent models of ALK-positive ALCL and induces regression of established Karpas-299 lymphomas. TAE684 displays appreciable bioavailability and half-life in vivo.
    TAE684 (1, 3, and 10 mg/kg. p.o.) significantly delays in lymphoma development and shows 100- to 1,000-fold reduction in luminescence signal. The TAE684- (10 mg/kg) treated group appeares healthy and does not display any signs of compound- or disease-related toxicity[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    614.20

    Appearance

    Solid

    Formula

    C30H40ClN7O3S
    CAS No.
    SMILES

    O=S(C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCC(N5CCN(CC5)C)CC4)C=C3OC)=NC=C2Cl)(C(C)C)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 7.69 mg/mL (12.52 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6281 mL 8.1407 mL 16.2813 mL
    5 mM 0.3256 mL 1.6281 mL 3.2563 mL
    10 mM 0.1628 mL 0.8141 mL 1.6281 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 0.77 mg/mL (1.25 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 0.77 mg/mL (1.25 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation
    References
    Cell Assay
    [1]

    Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, BCR-ABL, or TEL-kinase fusion constructs are plated in 384-well plates (25,000 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2-3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. ICsub>50 values are generated by using XLFit software.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    For in vivo compound efficacy studies, treatment is initiated 72 h after tail vein injection of 1×106 Karpas-299-, Ba/F3 NPM-ALK- or BCR-ABL-expressing cells into female Fox Chase SCIDBeige mice. Mice (n=10 per group) are administered either TAE684 resuspended in 10% 1-methyl-2-pyrrolidinone/90% PEG 300 solution at 1, 3, and 10 mg/kg once daily for 3 weeks or the vehicle solution at the same dosing schedule. Disease progression and compound efficacy is monitored weekly with bioluminescence imaging. To determine the efficacy of TAE684 on established disease, dosing is initiated on day 12, at which time the disease confirmed to be widespread by bioluminescence imaging. For analysis of downstream molecular effects in vivo, mice with established lymphomas are administered vehicle solution or TAE684 (10 mg/kg) for 3 days. At the end of treatment, mice are killed, and lymph nodes are extracted for immunoblotting and histological analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    NVP-TAE 684761439-42-3TAE 684TAE684TAE-684Anaplastic lymphoma kinase (ALK)ApoptosisAnaplastic lymphoma kinaseALK tyrosine kinase receptorCD246Cluster of differentiation 246Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email address *

    Phone number *

    		 

    Organization name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    NVP-TAE 684
    Cat. No.:
    HY-10192
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email address *

    Phone number

    		 

    Department *

    Organization name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.